Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
about
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)How I treat autoimmune lymphoproliferative syndromeUse of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndromeApproaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative SyndromeAutoimmune lymphoproliferative syndrome: an update and review of the literatureTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesDiagnosis and management of autoimmune cytopenias in childhood.HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE.ALPS-ten lessons from an international workshop on a genetic disease of apoptosisNew advances in the diagnosis and treatment of autoimmune lymphoproliferative syndromeTargeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaSirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Genetic defects of apoptosis and primary immunodeficiency.Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS)Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesOptimal Management of Autoimmune Lymphoproliferative Syndrome in Children.Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.Induction of tolerance to factor VIII by transient co-administration with rapamycin.Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.Inhibition of FAK prevents blister formation in the neonatal mouse model of pemphigus vulgaris.Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).Targeting Notch signaling in autoimmune and lymphoproliferative disease.Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.Autoimmune pancreatitis in MRL/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment
P2860
Q24623371-21C6C2D4-C3FA-4A4B-B447-09D3FD22BD26Q24633207-B6F586D6-21A8-45C2-A062-0238B1A3B069Q24643047-CDF9EDB2-DB66-459C-9D84-4CA61D0149B7Q24650472-64411902-6B10-41B8-AECF-E26B581945AFQ26799956-783C3577-F556-415F-97A8-2908C09FED0AQ26825740-18F9DC5C-B170-4F20-B783-9E5EE645379DQ26829652-E6C12736-2CC6-4A43-8D3F-DFE591CBFD39Q33411497-5FAFEFB0-CA16-44F9-962F-1A2FBAB1A21FQ33717763-B40A0C1C-8524-49AD-B36F-74A70B1D53DBQ33807422-3F4C2592-DA66-497F-8E54-3BA0E249D6C8Q34239719-82480B0D-48BE-4AAE-881D-898F15D0FAD7Q36352535-62A49153-B9FE-447F-9A64-7C44698FD5F8Q36443121-E7F2C0C9-57D3-4293-9B65-81FBEB499CCFQ37074284-5A925E96-E556-4750-9F6C-98231424CF2FQ37142878-9273F716-8C6B-4C86-A18E-23A571D338E9Q37219274-EC46F1EB-C1E9-4382-B6BD-E1A6C64CC366Q37248354-C7517F14-9C16-4787-9DDF-16C936348677Q37432231-946639B0-4C04-447A-A8BA-AF4ED3AC8505Q38823961-82387051-2308-4E49-83F7-F0B8F685D8DCQ39044467-D0258B48-3F02-4575-B339-F5D17A5BB14FQ40485786-DFC1E5CF-D077-40A2-ADFB-899997BF849CQ41824863-C5F3A449-1ABC-49A3-9E45-27745DC859C0Q42325007-A6802C5D-E754-404F-AA1B-971F3B287381Q42501870-78BCBC07-29CF-4C05-86DB-CC38FE465595Q42700395-1C1200ED-21A6-4039-A6D9-B63E725AA71BQ42953771-349C6691-4ACE-4A2A-83B2-E23227AC46B2Q47151016-87083096-BC30-46D0-998C-71DFB9ED2955Q50148782-5A4BB54E-C3FC-4045-9278-AE285A327050Q53239928-D20A207D-BF31-4C6E-B5D6-849E6B26EF9FQ56897015-1133BAF0-1382-4B03-8A12-5D5821BA8B23
P2860
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@ast
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@en
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@nl
type
label
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@ast
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@en
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@nl
prefLabel
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@ast
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@en
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@nl
P2093
P2860
P50
P1433
P1476
Rapamycin improves lymphoproli ...... oproliferative syndrome (ALPS)
@en
P2093
Dana A Obzut
Jessica Hulitt
John K Choi
John M Maris
Junior Hall
Kelly Axsom
Kelly C Goldsmith
Nicholas Rhodin
Stephan A Grupp
Valerie I Brown
P2860
P304
P356
10.1182/BLOOD-2006-01-010124
P407
P577
2006-06-06T00:00:00Z